Olmesartan (RNH 6270) is an Angiotensin II Type I receptor antagonist. Olmesartan is the active form of the antihypertensive drug olmesartan medoxomil,and has antihypertensive activity.

在接受olmesartan治疗的患者中，近80%达到了目标血压(<130/80 mm Hg)，而服用安慰剂的患者中有71%达标；临床测量的血压显示，olmesartan组的患者比安慰剂组低3.1/1.9 mm Hg。在olmesartan组中，8.2%的患者（2160名可评估患者中的178名）发展为微量白蛋白尿；而在安慰剂组为9.8%（2139名中的210名）；olmesartan使得微量白蛋白尿出现的时间延长了23%（微量白蛋白尿发生的危险比率为0.77；95%置信区间，0.63到0.94；P=0.01）。每个组中1%的患者血清肌酐水平翻倍。与安慰剂组相比，olmesartan组的非致命心血管事件略少——2232名患者中有81名（3.6%）相比于2215名患者中的91名（4.1%）（P=0.37），但是致命心血管事件的数量更多——15名患者（0.7%）相较于3名患者（0.1%）（P=0.01），这一差异部分归因于既往有冠状动脉心脏病的患者中，olmesartan组死于心血管原因的比率高于安慰剂组（564名患者中的11名[2.0%]对比540名中的1名[0.2%]，P=0.02）。

In a randomized, double-blind, multicenter, controlled trial, Assigned 4447 patients with type 2 diabetes to receive olmesartan (at a dose of 40 mg once daily) or placebo for a median of 3.2 years.?Additional antihypertensive drugs (except angiotensin-converting-enzyme inhibitors or ARBs) were used as needed to lower blood pressure to less than 130/80 mm Hg. The primary outcome was the time to the first onset of microalbuminuria.?The times to the onset of renal and cardiovascular events were analyzed as secondary end points[1].